ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.
“We are very pleased with the engagement from the cancer community in our TAPUR Study,” said ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO. “This growth in the study will help further our understanding of how these targeted therapies perform in patients with advanced cancer who have exhausted all other treatment options.”
Recently, 8 new centers in 36 locations signed on to begin offering the TAPUR Study at their locations within the next few months:
This brings the total number of TAPUR sites to 101 in 20 states, a nearly 3-fold increase since the trial launched just over a year ago at 35 sites. At these sites, a total of 17 drugs yielding 15 different targeted therapy options (some drugs are used in combination) are available, which are provided by the 7 pharmaceutical companies currently participating: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Merck, and Pfizer.
In addition, the study protocol, with cooperation from stakeholders, has been revised to lower the age of eligibility into the trial. The revision decreases the enrollment age from 18 to 12 years to extend the opportunity for participation to adolescent patients with advanced cancer where there is a defined adolescent dose for the study drugs. This protocol revision was recently approved by the Institutional Review Board and will be implemented soon.
In an effort to expand eligibility and facilitate logistics, the TAPUR team is engaging in several new collaborations with:
ASCO's global coordination also extends to the Netherlands, where the Society continues to work with the Netherlands Center for Personalized Cancer Treatment on its Drug Rediscovery Protocol (DRUP) trial, a protocol independently developed but very similar to TAPUR that allows international data-sharing. The DRUP study is accruing participants in more than 18 sites, and 160 patients have been submitted.
ASCO also works with the Research Advocacy Network (RAN) on a substudy that was developed to provide insights to help the oncology community understand how tumor genomic testing is being used by clinical oncologists and how to provide assistance with provider and patient education. The TAPUR substudy also collects follow-up information from oncologists participating in the TAPUR Study to understand the changes in their confidence in and use of tumor genomic testing after being involved in TAPUR. Currently more than 100 physicians across 54 TAPUR sites are participating in the TAPUR substudy.
The TAPUR Study is registered on ClinicalTrials.gov (NCT02693535), which includes a full list of inclusion/exclusion criteria and other information. Patients can find study information such as general eligibility criteria, participating clinical sites, and contact information for the study team at www.TAPUR.org. Researchers and practices interested in participating can visit the TAPUR study website for more information or contact the study team at: http://www.tapur.org/contact-us.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.